Pipeline and R&D

At Biosensors our pipeline uniquely positions us as a leading provider of advanced drug eluting stent stent designs and innovative combination device products in the interventional cardiology, peripheral vascular and critical care markets. Our future will be largely attributable to our aggressive internal research and development (R&D) efforts of the past and present, and our strong product development pipeline.

Initially, we focused our R&D on vascular catheters and blood pressure transducer systems for open-heart surgery and critical care. We are now developing future generation drug-eluting stents and other innovative products to address the challenges of cardiovascular disease, the worlds leading health problem.

Our capabilities are unique among medical device companies due to the development of our own proprietary antirestenosis drug compound delivered via a biodegradable coating that enhances the performance and safety of the stents we manufacture and sell. For example, our proprietary Biolimus A9™ anti-restenotic drug (BA9™) and our groundbreaking research into the synthesis and application of biodegradable stent coatings for anti-restenotic drug delivery have given us a clear technology lead.

We are the first company to offer a commercially available abluminal drug-eluting stent with a biodegradable coated, limus-eluting technology on our proven stent platform, the S-Stent™. In addition, one of our key R&D initiatives in the interventional cardiology field is a "polymer-free" drug-eluting stent system coated with our proprietary BA9™ antirestenosis drug.

Looking into the future, by developing and combining our expertise in stent design, polymer coating technology, and anti-restenotic drugs together into one design team, plus our in-depth knowledge of BA9™ in-vivo drug pharmacokinetics (PK), biodegradable coatings and advanced stent design technologies, we aim to rapidly develop highly effective and safe new drug eluting stent designs to address the evolving needs of the cardiology community.